News

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

How do psychiatrists feel about the current polycrises? “Overwhelmed.”

Vincenzo Di Nicola discusses the importance of pluralism in social psychiatry and the need for culturally relevant psychotherapy at the 2025 APA Annual Meeting.

Learn more about the critical link between early adversity and psychosis, and the need for targeted interventions and preventive measures.

Online dating transforms connections but often leads to loneliness and mental health issues. How can we encourage safer, more meaningful interactions?

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

Psychiatrists united in Los Angeles for a rally, advocating for mental health funding amidst growing concerns over service cuts and societal challenges.

Early intervention in schizophrenia enhances recovery, reduces symptoms, and improves quality of life through coordinated specialty care programs across the US.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Explore the urgent need for collaboration in mental health to combat societal crises and promote prosocial behavior for a healthier future.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Ramaswamy Viswanathan, MD, DrMedSc, emphasizes the vital role of lifestyle in mental health treatment and advocates for holistic approaches to prevent premature death at the 2025 APA Annual Meeting.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Our board members are presenting at this year's APA Annual Meeting. Be sure to check out their sessions!

The Osheroff v. Chestnut Lodge case had a transformative impact on psychiatric practices and the evolving relationship between science and religion.

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

Psychiatrists can leverage media to reshape mental health narratives, combat misinformation, and engage with the public, in a way that fosters open conversations and reduces stigma.

Mental health professionals should navigate media engagement by upholding ethical standards, ensuring informed consent, and combating misinformation to promote public awareness.

Uncertainty fuels anxiety, yet knowing outcomes—even grim ones—can bring relief.

Check out this year's Gerald F. Berlin Prize winner!

Badr Ratnakaran, MBBS, Psychiatric Times' new Climate Change Section Editor, explores the intersection of climate change and mental health, highlighting the urgent need for awareness and support in clinical practice.

"And I feel closer to him than 50 minutes should allow, a puzzled sensation, I’ve known him all my life..."

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.